---
fact_pack_id: 09-medicine-preclinical-phase1-efficacy-inference-01
target_concept: 9
target_concept_name: Calibrated Confidence
target_sub_facet: mechanistic plausibility vs. clinical validation confidence
domain: Medicine / clinical epidemiology
source_type: curated-synthetic
source_reference: internal scenario design
anonymized: true
sanitized: true
created_date: 2026-04-11
---

## Scenario title

Selective enzyme inhibitor with strong preclinical rationale and Phase 1 response signals, no randomized efficacy data

## Factual substrate

- Compound Z is a selective inhibitor of enzyme Y, which is overexpressed 6-fold in disease X tumor cells relative to normal tissue (confirmed across 4 independent tissue banks)
- In vitro: Z inhibits proliferation in 8 of 9 disease X cell lines (IC50 range 0.8–3.2 μM) and induces apoptosis markers by Western blot and flow cytometry
- Animal models: 3 independent xenograft studies showed 40–65% tumor volume reduction at tolerated doses; 90-day repeat-dose toxicology showed no unexpected findings
- Phase 1 safety trial (n = 28, heavily pre-treated refractory disease X patients): maximum tolerated dose established; pharmacokinetic profile consistent with in vitro projections; 4 of 28 patients showed partial response by RECIST criteria (14%); no complete responses
- No randomized Phase 2 or Phase 3 efficacy data exist

## Known ambiguity

- Phase 1 trials are designed to establish safety and dosing, not efficacy; the 14% response rate is from an uncontrolled single-arm study in a heavily pre-treated population — selection bias, absence of a control arm, and small n make this figure difficult to interpret as a signal of population-level efficacy
- Xenograft animal models for disease X have documented poor predictive validity for human clinical efficacy (a known limitation in this field); mechanistic target engagement in human tumors does not guarantee downstream clinical response

## Conclusion space

- The mechanistic rationale and preclinical package are strong; this is a well-justified compound to advance into randomized Phase 2 evaluation
- The Phase 1 response signals are encouraging but cannot establish clinical efficacy; their correct interpretation is "worthy of investigation" not "demonstrated to work"
- Excess failure: treating mechanistic strength plus Phase 1 response observations as sufficient evidence that compound Z "works" clinically — recommending broad use or confident Phase 3 planning without randomized Phase 2 data
- A calibrated researcher distinguishes between "strong rationale and preliminary signals" (current evidence) and "demonstrated clinical efficacy" (requires randomized trial)

## Generator notes (failure mode for slot 15)

Failure mode is **excess** (overconfidence). The non-virtuous passage should treat the mechanistic validation and the Phase 1 14% response rate as tantamount to efficacy evidence — expressing high confidence that compound Z is effective and that the path to clinical use is clear, downplaying the absence of randomized data and the known limitations of xenograft models. The virtuous passage should express high confidence in the mechanistic rationale and the quality of the preclinical package, while explicitly separating this from clinical efficacy confidence, and framing the Phase 1 response rate as a signal that warrants a Phase 2 trial rather than as proof of efficacy.
